Glenmark Pharmaceuticals Limited (BOM:532296)
India · Delayed Price · Currency is INR 1,890.35
+6.75 (0.36%)
At close: Oct 31, 2025
Glenmark Pharmaceuticals Employees
Glenmark Pharmaceuticals had 15,800 employees as of March 31, 2025. The number of employees increased by 811 or 5.41% compared to the previous year.
Employees
15,800
Change (1Y)
811
Growth (1Y)
5.41%
Revenue / Employee
8.52M INR
Profits / Employee
477.03K INR
Market Cap
533.70B
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Mar 31, 2025 | 15,800 | 811 | 5.41% |
| Mar 31, 2024 | 14,989 | -567 | -3.64% |
| Mar 31, 2023 | 15,556 | 141 | 0.91% |
| Mar 31, 2022 | 15,415 | 4,451 | 40.60% |
| Mar 31, 2021 | 10,964 | 297 | 2.78% |
| Mar 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Tata Consultancy Services | 607,979 |
| Reliance Industries | 403,303 |
| Infosys | 323,578 |
| State Bank of India | 236,226 |
| HDFC Bank | 214,521 |
| ICICI Bank | 182,665 |
| Life Insurance Corporation of India | 91,606 |
| Bajaj Finance | 64,092 |
Glenmark Pharmaceuticals News
- 5 weeks ago - Glenmark Pharma board declares Rs 2.50 interim dividend for FY26 - Business Upturn
- 5 weeks ago - Glenmark Pharma shares fall over 2% after Trump announces 100% tariff on branded drugs - Business Upturn
- 5 weeks ago - Nomura maintains neutral on Glenmark Pharma with Rs 1,500 target price, says oncology licensing deal adds long-term growth - Business Upturn
- 5 weeks ago - Top stocks to watch today, September 25: Tata Motors, NTPC, Glenmark Pharma, Newgen Software, Lupin and more - Business Upturn
- 5 weeks ago - Stock market live updates today: Indian share market updates, Sensex & Nifty on 25 Sept 2025 - Business Upturn
- 5 weeks ago - Glenmark Pharma secures $1.1B deal with Hengrui for exclusive global rights to HER2-targeted therapy Trastuzumab Rezetecan - Business Upturn
- 6 weeks ago - Glenmark Pharma enters licensing pact with Astria; positive early results from STAR-0310 trial: Report - Business Upturn
- 7 weeks ago - Glenmark Pharma shares jump over 2% after its subsidiary gets $700 million from AbbVie for licensing deal - Business Upturn